

4

FORM PTO-1449 (Modified)	Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
LIST OF PATENTS AND PUBLICATIONS	Applicant: DALE B. SCHENK et al.	
APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Filing Date: May 26, 2000	Group: 1641

Reference Designation	U.S. PATENT DOCUMENTS	Page 1
-----------------------	-----------------------	--------

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
81	AA	5,958,883	9/28/99	Snow		
	AB	5,955,317	9/21/99	Suzuki et al.		
	AC	5,955,079	9/21/99	Mond et al.		
	AD	5,877,399	3/2/99	Hsiao et al.		
	AE	5,869,093	2/9/99	Weiner et al.		
	AF	5,869,054	2/9/99	Weiner et al.		
	AG	5,854,204	12/29/98	Findeis et al.		
	AH	5,851,996	12/22/98	Kline		
	AI	5,849,298	12/15/98	Weiner et al.		
	AJ	5,837,473	11/17/98	Maggio et al.		
	AK	5,786,180	7/28/98	Konig et al.		
	AL	5,753,624	5/19/98	McMichael et al.		
	AM	5,750,349	5/12/98	Suzuki et al.		
	AN	5,733,547	3/31/98	Weiner et al.		
	AO	5,688,651	11/18/97	Solomon		
	AP	5,679,348	10/21/97	Nesburn et al.		
	AQ	5,645,820	7/8/97	Hafler et al.		
	AR	5,641,474	6/24/97	Hafler et al.		
	AS	5,641,473	6/24/97	Hafler et al.		
	AT	5,612,486	3/18/97	McConlogue et al.		
	AU	5,605,811	2/25/97	Seubert et al.		
	AV	5,585,100	12/17/96	Mond et al.		
	AW	5,571,500	11/5/96	Hafler et al.		
	AX	5,571,499	11/5/96	Hafler et al.		
	AY	5,434,170	7/18/95	Andrulis et al.		
	AZ	5,387,742	2/7/95	Cordell		
	BA	5,231,000	7/27/93	Majocha et al.		
	BB	5,220,013	6/15/93	Ponte et al.		
	BC	5,208,036	5/4/93	Eppstein et al.		
	BD	5,192,753	3/9/93	McGeer et al.		
	BE	5,057,540	10/15/91	Kensil et al.		
81	BF	4,666,829	5/19/85	Glenner er al.		

RECEIVED


NOV 07 2000

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
--------------------------	--	--	--	--	--	--

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
81	BG	WO 99/60024	11/25/99	PCT		



FORM PTO-1449 (Modified)			Attorney Docket No.: 15270J-004760US		Application No.: 09/580,018	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: DALE B. SCHENK et al.			
			Filing Date: May 26, 2000		Group: 1641	
<u>80</u> BH	WO 99/60021	11/25/99	PCT			
BI	WO 99/58564	11/18/99	PCT			
BJ	WO 99/27949	6/10/99	PCT			
BK	WO 99/27944	6/10/99	PCT			
BL	WO 99/27911	6/10/99	PCT			
BM	WO 99/06066	2/11/99	PCT			
BN	WO 98/44955	10/15/98	PCT			
BO	WO 98/07850	2/26/98	PCT			
BP	WO 97/17613	5/15/97	PCT			
BQ	WO 96/39176	12/12/96	PCT			
BR	WO 96/25435	8/22/96	PCT			
BS	WO 96/18900	6/20/96	PCT			
BT	WO 95/31996	11/30/95	PCT			
BU	WO 95/11311	4/27/95	PCT			
BV	WO 95/05853	3/2/95	PCT			
BW	WO 95/04151	2/9/95	PCT			
BX	WO 94/03615	2/17/94	PCT			
BY	WO 94/01772	1/20/94	PCT			
BZ	WO 93/21950	11/11/93	PCT			
CA	WO 93/16724	9/2/93	PCT			
CB	WO 93/15760	8/19/93	PCT			
CC	WO 93/14200	7/22/93	PCT			
CD	WO 93/02189	2/4/93	PCT			
CE	WO 92/13069	8/6/92	PCT			
CF	WO 92/06708	4/30/92	PCT			
CG	WO 92/06187	4/16/92	PCT			
CH	WO 91/16819	11/14/91	PCT			
CI	WO 91/19810	12/26/91	PCT			
CJ	WO 91/12816	9/5/91	PCT			
CK	WO 91/08760	6/27/91	PCT			
CL	WO 90/12871	11/1/90	PCT			
CM	WO 90/12870	11/1/90	PCT			
CN	WO 89/06242	7/13/89	PCT			
CO	WO 89/06689	7/27/89	PCT			
CP	WO 89/03687	5/5/89	PCT			
CQ	WO 88/10120	12/29/88	PCT			
CR	EP 506 785	3/15/00	Europe			
<u>80</u> CS	EP 639 081	11/3/99	Europe			




RECEIVED


NOV 07 2000

TECH CENTER 1500/2900

FORM PTO-1449 (Modified)				Attorney Docket No.: 15270J-004760US		Application No.: 09/580,018	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: DALE B. SCHENK et al.			
				Filing Date: May 16, 2000		Group: 1641	
<u>80</u> CT	EP 561 087	8/4/99	Europe				
CU	EP 526 511	5/28/97	Europe				
CV	EP 911 036	4/28/99	Europe				
CW	EP 652 962	12/16/98	Europe				
CX	EP 868 918	10/7/98	Europe				
CY	EP 863 211	9/9/98	Europe				
CZ	EP 845 270	6/3/98	Europe				
DA	EP 594 607	8/27/97	Europe				
DB	EP 782 859	7/9/97	Europe				
DC	EP 440 619	1/24/96	Europe				
DD	EP 359 783	11/29/95	Europe				
DE	EP 683 234	11/22/95	Europe				
DF	EP 666 080	8/9/95	Europe				
DG	EP 451 700	10/16/91	Europe				
DH	EP 276 723	12/8/93	Europe				
DI	GB 2 335 192	9/15/99	United Kingdom				
<u>80</u> DJ	GB 2 220 211	1/4/90	United Kingdom				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
<u>80</u> DK	Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," <u>Neurology</u> , 45:1441-1445 (1995).						
DL	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).						
DM	Bauer et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).						
DN	Blass, John P., "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).						
DO	Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).						
DP	Borchelt et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).						
DQ	Boris-Lawrie et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genet Develop.</u> , 3: 102-109 (1993).						
DR	Brice et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).						
DS	Chao et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513.7 (1993).						
DT	Duff et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995)						
DU	Elizan et al., "Antineurofilament antibodies in a postencephalitic and idiopathic parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).						
DV	Felsenstein et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).						
<u>80</u> DW	Finch et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).						



FORM PTO-1449 (Modified)		Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION AND DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: DALE B. SCHENK et al.	
		Filing Date: May 26, 2000	Group: 1641
<input checked="" type="checkbox"/> DX	Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).		
<input type="checkbox"/> DY	Flanders et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).		
<input type="checkbox"/> DZ	Games et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein", <u>Nature</u> , 373(6514): 523-527 (1995).		
<input type="checkbox"/> EA	Gandy et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).		
<input type="checkbox"/> EB	Gaskin et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).		
<input type="checkbox"/> EC	Glenn et al., "Skin immunization made possible by cholera toxin", <u>Nature</u> , 391: 851 (1998).		
<input type="checkbox"/> ED	Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).		
<input type="checkbox"/> EE	Glenner et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein", <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).		
<input type="checkbox"/> EF	Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).		
<input type="checkbox"/> EG	Gozes et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).		
<input type="checkbox"/> EH	Gupta et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs", <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).		
<input type="checkbox"/> EI	Haga et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).		
<input type="checkbox"/> EJ	Hanes et al., "New advances in microsphere-based single-dose vaccines", <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).		
<input type="checkbox"/> EK	Hardy, "Amyloid, the presenilins and Alzheimer's disease", <u>TINS</u> , 20(4): 154-159 (1997).		
<input type="checkbox"/> EL	Hardy, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).		
<input type="checkbox"/> EM	Hsiao et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice", <u>Science</u> , 274: 99-102 (1996).		
<input type="checkbox"/> EN	Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).		
<input type="checkbox"/> EO	Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).		
<input type="checkbox"/> EP	Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).		
<input type="checkbox"/> EQ	Jansen et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity", <u>Immun. Rev.</u> , 62: 185-216 (1982).		
<input type="checkbox"/> ER	Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).		
<input type="checkbox"/> ES	Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).		
<input type="checkbox"/> ET	Lampert-Etchells et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).		
<input type="checkbox"/> EU	Langer, "New Methods of Drug Delivery", <u>Science</u> , 249: 1527-1532 (1990).		
<input checked="" type="checkbox"/> EV	Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).		




FORM PTO-1449 (Modified)		Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION AND DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: DALE B. SCHENK et al.	
		Filing Date: May 26, 2000	Group: 1641
<u>EW</u>	Lemere et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, 10/23-28/99.		
EX	Livingston et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection", <u>J. Immunol.</u> , 159: 1383-1392 (1997).		
EY	Lopez et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).		
EZ	McGee et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility", <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).		
FA	Meda et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995).		
FB	Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).		
FC	Nathanson et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic", <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).		
FD	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).		
FE	Paresce et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).		
FF	Paul et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers", <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).		
FG	Prieels et al., "Synergistic adjuvants for vaccines", <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).		
FH	Quon et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).		
FI	Raso, V. A., "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (4/2/98).		
FJ	Rogers et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).		
FK	Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).		
FL	Selkoe, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).		
FM	Selkoe, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (11/91).		
FN	Selkoe, Dennis J., "In the Beginning...", <u>Nature</u> , 354:432-433 (1991).		
FO	Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).		
FP	Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).		
FQ	Selkoe, "Alzheimer's Disease: A Central Role for Amyloid", <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).		
FR	Selkoe, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease", <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).		
FS	Seubert et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> , 359: 325-327 (1992).		
FT	Shiosaka, Sadao, "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).		
FU	Smits et al., "Prion Protein and Scrapie Susceptibility", <u>Vet. Quart.</u> , 19(3): 101-105 (1997).		
FV	Solomon et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).		
<u>FW</u>	Solomon et al., "Monoclonal antibodies inhibit in <i>vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).		
FX	Solomon, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center <i>improper format</i>		
FY	Solomon, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel. <i>improper format</i>		
<u>FZ</u>	Stoute et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria", <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).		

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: DALE B. SCHENK et al.	
		Filing Date: May 26, 2000	Group: 1641
<u>GA</u>	Sturchler-Pierrat et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology", <u>PNAS</u> , 94: 13287-13292 (1997).		
<u>GB</u>	Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).		
<u>GC</u>	Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).		
<u>GD</u>	Verbeek et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).		
<u>GE</u>	Walker et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).		
<u>GF</u>	Wengenack et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-824 (2000).		
<u>GG</u>	Weiner et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).		
<u>GH</u>	Weissmann et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease", <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).		
<u>GI</u>	Wood et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease", <u>PNAS</u> , 94: 1550-1555 (1997).		
<u>GJ</u>	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/Graduate School of Medicine, Knoxville, Tennessee. improper format		
EXAMINER <u>SSum</u> DATE CONSIDERED <u>12-5-02</u>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

6



FORM PTO-1449 (Modified)			Attorney Docket No.: 15270J-004760US		Application No.: 09/580,018	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION AND CLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Schenk et al.			
			Filing Date: May 26, 2000		Group: 1641	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AA	EP 613 007	8/31/94	Europe			
AB	WO 95/11994	5/4/95	PCT			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AC	Schenk et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).					
AD	Van Gool et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).					
EXAMINER			DATE CONSIDERED 12-5-02			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JAN 12 2001

TECH CENTER 1800/2900

Please type a plus sign (+) inside this box

+

#11

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/580,018
Filing Date	05/26/00
First Named Inventor	Dale B. Schenk
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	15270J-004760US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
20	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	207	5,780,587		Potter	07-14-1998	
	197	5,744,368		Goldgaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	175	5,441,870		Seubert, et al.	08-15-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	32	5,187,153		Cordell et al.	02-16-93	
	198	5,004,697		Pardridge	04-0201991	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
20	187	EP	783 104	A1		07-09-1997		<input type="checkbox"/>
	199	PCT	00/77178	A1		12-21-2000		<input type="checkbox"/>
	188	PCT	00/43049	A1		07-27-2000		<input type="checkbox"/>
	203	PCT	99/00150	A2		01-07-1999		<input type="checkbox"/>
	202	PCT	97/21728	A1		06-19-1997		<input type="checkbox"/>
	208	PCT	96/28471	A1		09-19-1996		<input type="checkbox"/>
	200	PCT	95/12815	A1		05-11-1995		<input type="checkbox"/>
	201	PCT	94/28412	A1		12-08-1994		<input type="checkbox"/>
	205	PCT	93/04194	A1		03-04-1993		<input type="checkbox"/>
	87	PCT	89/01343	A1		02-23-1989		<input type="checkbox"/>

Examiner Signature

[Signature]

Date Considered

12-05-02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3163030 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete If Known

Application Number	09/580,018
Filing Date	05/26/00
First Named Inventor	Dale B. Schenk
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	15270J-004760US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> 18:764 (1992).	<input type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input type="checkbox"/>
	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> 125:223-226 (1991).	<input type="checkbox"/>
	214	DEMATOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001).	<input type="checkbox"/>
	210	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).	<input type="checkbox"/>
	215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).	<input type="checkbox"/>
	190	GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).	<input type="checkbox"/>
	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	<input type="checkbox"/>
	177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	<input type="checkbox"/>
	192	IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994).	<input type="checkbox"/>
	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-378 (1991).	<input type="checkbox"/>
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	<input type="checkbox"/>
	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	<input type="checkbox"/>
		218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> 33:2184-2189 (1992).

Examiner
Signature

Date
Considered

12-08-02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3163030 v1

Please type a plus sign (+) inside this box

+



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet 3 of 3

Application Number 09/580,018
Filing Date 05/26/00
First Named Inventor Dale B. Schenk
Group Art Unit 1641
Examiner Name Unassigned
Attorney Docket Number 15270J-004760US

217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	<input type="checkbox"/>
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).	<input type="checkbox"/>
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	<input type="checkbox"/>
144	RASO, V.A.; Grant application # 1-R49-AG1-5746-01; (publication date unknown); improper format	<input type="checkbox"/>
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	<input type="checkbox"/>
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	<input type="checkbox"/>
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	<input type="checkbox"/>
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	<input type="checkbox"/>
182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	<input type="checkbox"/>
184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).	<input type="checkbox"/>
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	<input type="checkbox"/>
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date ---unknown); improper format	<input type="checkbox"/>
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	<input type="checkbox"/>
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	<input type="checkbox"/>
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8729-8732 (1985).	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date
Considered

12-08-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3163030 v1